Background: Mapping memory ability is highly correlated with an orienteer's level, and spatial memory tasks of different difficulties can reveal the spatial cognitive characteristics of high-level athletes.

Methods: An "expert-novice" experimental paradigm was used to monitor behavioral performance and changes in cerebral blood oxygen concentration in orienteering athletes with tasks of different difficulty and cognitive load using functional near-infrared spectroscopic imaging (fNIRS).

Results: (1) there was no difference between high-/low-level athletes' map recognition and memory abilities in the non-orienteering scenario; (2) with increasing task difficulty, both high-/low-level athletes showed significantly decreasing behavioral performance, reduced correctness, longer reaction time, and strengthened cerebral blood oxygen activation concentration. There was no significant difference in L-DLPFC cerebral oxygen concentration between high-/low-level athletes in the simple map task, and the cerebral oxygen concentration in all brain regions was lower in the expert group than in the novice group in the rest of the task difficulty levels; (3) the correctness rate in the expert group in the complex task was closely related to the activation of the right hemisphere (R-DLPFC, R-VLPFC).

Conclusions: Experts have a specific cognitive advantage in map-recognition memory, showing higher task performance and lower cerebral blood oxygen activation; cognitive load constrains map-recognition memory-specific ability and produces different performance effects and brain activation changes on spatial memory processing.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688589PMC
http://dx.doi.org/10.3390/brainsci12111561DOI Listing

Publication Analysis

Top Keywords

cerebral blood
12
blood oxygen
12
oxygen concentration
12
map-recognition memory
8
memory ability
8
spatial memory
8
behavioral performance
8
cognitive load
8
task difficulty
8
high-/low-level athletes
8

Similar Publications

Glioblastoma (GBM) is the most common malignant primary brain tumor, with a mean survival of less than 2 years. Unique brain structures and the microenvironment, including blood-brain barriers, put great challenges on clinical drug development. Sophoricoside (Sop), an isoflavone glycoside isolated from seeds of Sophora japonica L.

View Article and Find Full Text PDF

Introduction: Plasma phosphorylated tau (p-tau) biomarkers have improved Alzheimer's disease (AD) diagnosis, but data from diverse Asian populations are limited. This study evaluated plasma p-tau217 and p-tau181 levels in Korean and Taiwanese populations.

Methods: All participants (n = 270) underwent amyloid positron emission tomography (PET) and blood tests.

View Article and Find Full Text PDF

Neurodevelopmental impairments associated with congenital heart disease (CHD) may arise from perturbations in brain developmental pathways, including the formation of sulcal patterns. While genetic factors contribute to sulcal features, the association of noncoding variants (ncDNVs) with sulcal patterns in people with CHD remains poorly understood. Leveraging deep learning models, we examined the predicted impact of ncDNVs on gene regulatory signals.

View Article and Find Full Text PDF

White Matter Injury in Central Nervous System Disorders.

Neuropsychiatr Dis Treat

January 2025

Department of Rehabilitation Medicine, The Affiliated Taian City Central Hospital of Qingdao University, Taian, 271000, People's Republic of China.

As the aging process accelerates and living conditions improve, central nervous system (CNS) diseases have become a major public health problem. Diseases of the CNS cause not only gray matter damage, which is primarily characterized by the loss of neurons, but also white matter damage. However, most previous studies have focused on grey matter injury (GMI), with fewer studies on white matter injury (WMI).

View Article and Find Full Text PDF

Major Depressive Disorder (MDD) is a widespread psychiatric condition impacting social and occupational functioning, making it a leading cause of disability. The diagnosis of MDD remains clinical, based on the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria, as biomarkers have not yet been validated for diagnostic purposes or as predictors of treatment response. Traditional treatment strategies often follow a one-size-fits-all approach obtaining suboptimal outcomes for many patients who fail to experience response or recovery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!